🚀 VC round data is live in beta, check it out!
Arovella Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arovella Therapeutics and similar public comparables like Nanexa, Herantis Pharma, Actuate Therapeutics, Oncocross and more.
Arovella Therapeutics Overview
About Arovella Therapeutics
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Founded
1999
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$52M
Arovella Therapeutics Financials
Arovella Therapeutics reported last 12-month revenue of $88K.
In the same LTM period, Arovella Therapeutics generated had net loss of ($5M).
Revenue (LTM)
Arovella Therapeutics P&L
In the most recent fiscal year, Arovella Therapeutics reported revenue of $94K and EBITDA of ($8M).
Arovella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $88K | XXX | $94K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $94K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8159%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (8237%) | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (5521%) | XXX | (5205%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arovella Therapeutics Stock Performance
Arovella Therapeutics has current market cap of $66M, and enterprise value of $52M.
Market Cap Evolution
Arovella Therapeutics' stock price is $0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $66M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArovella Therapeutics Valuation Multiples
Arovella Therapeutics trades at 592.8x EV/Revenue multiple, and (6.8x) EV/EBITDA.
EV / Revenue (LTM)
Arovella Therapeutics Financial Valuation Multiples
As of March 29, 2026, Arovella Therapeutics has market cap of $66M and EV of $52M.
Equity research analysts estimate Arovella Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arovella Therapeutics has a P/E ratio of (13.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/Revenue | 592.8x | XXX | 558.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (6.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 558.8x | XXX | XXX | XXX |
| P/E | (13.5x) | XXX | (13.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arovella Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arovella Therapeutics Margins & Growth Rates
Arovella Therapeutics' revenue in the last fiscal year grew by 78%.
Arovella Therapeutics' revenue per employee in the last FY averaged $0.0M.
Arovella Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 78% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8159%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 12% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2250% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4796% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 8337% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arovella Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanexa | XXX | XXX | XXX | XXX | XXX | XXX |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arovella Therapeutics M&A Activity
Arovella Therapeutics acquired XXX companies to date.
Last acquisition by Arovella Therapeutics was on XXXXXXXX, XXXXX. Arovella Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arovella Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArovella Therapeutics Investment Activity
Arovella Therapeutics invested in XXX companies to date.
Arovella Therapeutics made its latest investment on XXXXXXXX, XXXXX. Arovella Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arovella Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arovella Therapeutics
| When was Arovella Therapeutics founded? | Arovella Therapeutics was founded in 1999. |
| Where is Arovella Therapeutics headquartered? | Arovella Therapeutics is headquartered in Australia. |
| How many employees does Arovella Therapeutics have? | As of today, Arovella Therapeutics has over 14 employees. |
| Is Arovella Therapeutics publicly listed? | Yes, Arovella Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Arovella Therapeutics? | Arovella Therapeutics trades under ALA ticker. |
| When did Arovella Therapeutics go public? | Arovella Therapeutics went public in 2002. |
| Who are competitors of Arovella Therapeutics? | Arovella Therapeutics main competitors are Nanexa, Herantis Pharma, Actuate Therapeutics, Oncocross. |
| What is the current market cap of Arovella Therapeutics? | Arovella Therapeutics' current market cap is $66M. |
| What is the current revenue of Arovella Therapeutics? | Arovella Therapeutics' last 12 months revenue is $88K. |
| What is the current EV/Revenue multiple of Arovella Therapeutics? | Current revenue multiple of Arovella Therapeutics is 592.8x. |
| Is Arovella Therapeutics profitable? | No, Arovella Therapeutics is not profitable. |
| What is the current net income of Arovella Therapeutics? | Arovella Therapeutics' last 12 months net income is ($5M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.